| Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension |
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society's (ATS) 2025 International Conference in San Francisco from May 16-21. Data from nine presentations demonstrate Merck's commitment to advancing research for patients with this disease. Merck will present pooled data from participants who have comple. |
businesswire.com |
2025-05-16 10:45:00 |
Czytaj oryginał (ang.) |
| Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers |
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer. |
businesswire.com |
2025-05-15 10:45:00 |
Czytaj oryginał (ang.) |
| FDA Approves Merck's WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL) |
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG PPGL FDA Approval News Release. |
businesswire.com |
2025-05-14 21:15:00 |
Czytaj oryginał (ang.) |
| Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript) |
Merck & Co., Inc. (NYSE:MRK ) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ET Company Participants Jannie Oosthuizen - President Peter Dannenbaum - Senior Vice President, Investor Relations Marjorie Green - SVP, Head of Oncology Clinical Development Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us for this, meeting. I'm Tim Anderson, the U.S. large-cap pharma and biotech analyst at Bank of America. |
seekingalpha.com |
2025-05-14 20:50:26 |
Czytaj oryginał (ang.) |
| US FDA expands use of Merck's cancer drug for adrenal gland tumors |
The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two types adrenal gland tumors. |
reuters.com |
2025-05-14 16:48:56 |
Czytaj oryginał (ang.) |
| 3 Absurdly Cheap Stocks Trading Near Their 52-Week Lows |
Buying low and selling high is what investing comes down to. Often, however, investors get spooked when prices are low and avoid struggling stocks, thinking that they are destined to go even lower. |
fool.com |
2025-05-14 15:31:00 |
Czytaj oryginał (ang.) |
| Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck. |
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next. |
barrons.com |
2025-05-14 13:55:00 |
Czytaj oryginał (ang.) |
| Germany's Merck drops China surcharge on orders after US-China tariff deal |
German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China following the U.S.-China agreement to pause sky-high tariffs on each other, the company said Wednesday. |
reuters.com |
2025-05-14 12:46:36 |
Czytaj oryginał (ang.) |
| Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared |
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices. |
zacks.com |
2025-05-13 12:40:53 |
Czytaj oryginał (ang.) |
| Research on Novel Treatment Approaches and Scientific Advances From Merck's Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025 |
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research across more than 25 types of cancer and multiple treatment settings from the company's broad and differentiated portfolio and pipeline will be showcased at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30–June 3). Data highlight Merck's commitment to rapidly advance research across multiple tumor types and continue to build on its portfolio. |
businesswire.com |
2025-05-13 10:45:00 |
Czytaj oryginał (ang.) |
| Drugmakers are spared worst-case drug pricing scenario for now |
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan. |
wsj.com |
2025-05-12 17:14:00 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs |
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug. |
zacks.com |
2025-05-12 14:41:06 |
Czytaj oryginał (ang.) |
| Surprise Breakthrough: US-China Talks Spark Market Rally |
An unexpected thaw in US-China trade relations is sending US equity markets soaring this morning. |
zacks.com |
2025-05-12 14:00:56 |
Czytaj oryginał (ang.) |
| Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal |
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal. |
globenewswire.com |
2025-05-12 05:00:00 |
Czytaj oryginał (ang.) |
| Pressure is still on the pharma sector, says Mizuho's Jared Holz |
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector. |
youtube.com |
2025-05-08 23:23:04 |
Czytaj oryginał (ang.) |
| 2 Beaten-Down Stocks That Are Great Buys on the Dip |
Even when equities are volatile, investors can find great stocks to buy. And the rules for investing in the current environment aren't that different, at least for those focused on the long game: Find quality stocks likely to survive the somewhat challenging period we are experiencing and perform well over five years or more. |
fool.com |
2025-05-08 13:12:00 |
Czytaj oryginał (ang.) |
| Merck Animal Health announces $895 million investment in Kansas |
Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in De Soto, Kansas. |
reuters.com |
2025-05-08 11:22:15 |
Czytaj oryginał (ang.) |
| Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto |
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health's manufacturing facility in De Soto, Kansas. The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It inc. |
businesswire.com |
2025-05-08 10:45:00 |
Czytaj oryginał (ang.) |
| Big Blue Chip Dividends? Try These ‘Dogs' Up To 6.8% |
The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays. |
forbes.com |
2025-01-04 13:49:00 |
Czytaj oryginał (ang.) |
| January Dow Dogs: 1 'Safer' Buy, And 5 With Promise |
Verizon Communications is the only Dow Dog meeting the ideal of annual dividends from $1K invested, exceeding the single share price. Analysts forecast 11.36% to 31.73% net gains from the top ten Dow Dogs by January 2026, with Merck leading at $313.37. A market correction of 82% could make all top ‘safer' Dow dividend dogs fair-priced, with dividends from $1K invested meeting or exceeding share prices. |
seekingalpha.com |
2025-01-02 14:21:43 |
Czytaj oryginał (ang.) |
| Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-01-02 12:01:15 |
Czytaj oryginał (ang.) |
| 2025's Five Highest Yielding Dogs of the Dow Could Explode Higher |
The ‘Dogs of the Dow' is a well-known strategy first published in 1991 by Michael Higgins. |
247wallst.com |
2025-01-01 10:08:10 |
Czytaj oryginał (ang.) |
| UK approves Merck's therapy for rare lung condition |
UK's Medicines and Healthcare products Regulatory Agency (MHRA) said on Tuesday it had approved Merck's therapy to treat a rare lung condition called pulmonary arterial hypertension. |
reuters.com |
2024-12-31 09:48:58 |
Czytaj oryginał (ang.) |
| 2 High-Yield Dividend Stocks to Buy Early in 2025 |
The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (BMY -2.81%) and Merck & Co. (MRK -1.33%) stand out for their combination of above-average dividend yields and proven business models. |
fool.com |
2024-12-31 09:45:00 |
Czytaj oryginał (ang.) |
| Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know |
The latest trading day saw Merck (MRK) settling at $98.37, representing a -1.33% change from its previous close. |
zacks.com |
2024-12-30 20:56:10 |
Czytaj oryginał (ang.) |
| US Large Cap Dividend Stocks Should Roll in 2025: Our 4 Favorite Picks |
Large-capitalization dividend stocks are a favorite among investors for a good reason. |
247wallst.com |
2024-12-30 13:14:05 |
Czytaj oryginał (ang.) |
| 2 Reasons to Sell Merck Stock and 1 Reason to Buy |
There is plenty to like about Merck (MRK -0.25%). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. |
fool.com |
2024-12-26 11:45:00 |
Czytaj oryginał (ang.) |
| Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing |
Merck (MRK) closed the most recent trading day at $99.45, moving +0.08% from the previous trading session. |
zacks.com |
2024-12-24 20:51:34 |
Czytaj oryginał (ang.) |
| Merck to discontinue drug for bacterial infection |
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug Administration's website showed on Monday. |
reuters.com |
2024-12-23 20:43:21 |
Czytaj oryginał (ang.) |
| Merck: A Low-Hanging Fruit To Pick |
Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, is now a $258 billion (by market cap) healthcare behemoth. The US is the company's largest market, accounting for approximately 47% of worldwide sales. Merck has started showing signs of sustained growth starting from right about FY 2020, as Keytruda is growing way faster than 5% annually. |
seekingalpha.com |
2024-12-23 11:00:00 |
Czytaj oryginał (ang.) |
| Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More |
According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025. |
benzinga.com |
2024-12-22 16:51:34 |
Czytaj oryginał (ang.) |
| Is Merck the Next Big Weight-Loss Stock? |
Watch out, Eli Lilly and Novo Nordisk. Merck (MRK -1.48%) is hungrily looking to take a bite out of the weight-loss drugs market. |
fool.com |
2024-12-22 08:45:00 |
Czytaj oryginał (ang.) |
| Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture |
The CNBC 'Halftime Report' Investment Committee discusses today's market movers. |
youtube.com |
2024-12-20 16:05:25 |
Czytaj oryginał (ang.) |
| MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals |
Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection. |
zacks.com |
2024-12-20 12:21:08 |
Czytaj oryginał (ang.) |
| Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know |
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2024-12-20 12:06:15 |
Czytaj oryginał (ang.) |
| Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks |
Collecting dividend income on a recurring basis can help strengthen your financial position and be a way for you to be less dependent on other sources of cash flow. The one downside is that many dividend stocks only pay on a quarterly basis, which means that you'll often be waiting multiple months before the next dividend payment. |
fool.com |
2024-12-20 09:45:00 |
Czytaj oryginał (ang.) |
| Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody |
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. As previously announced, Merck will develop, manufacture and commercialize LM-299. Merck will record a pre-tax charge relating to the upfront payment of $588 million, or approximately $0.18 per share, in the company's fourth quarte. |
businesswire.com |
2024-12-20 08:45:00 |
Czytaj oryginał (ang.) |
| Stock Of The Day: Where Does The Merck Downtrend End? |
Shares of Merck & Co., Inc. MRK are trading flat on Thursday, but remain in a downtrend. |
benzinga.com |
2024-12-19 13:54:36 |
Czytaj oryginał (ang.) |